When cancer cells start to grow uncontrollably, the mTORnormal checkpoints and developmental programming become hijacked by signals emitted from the tumorous growth. One common side effect of chemotherapy and other forms of cancer treatment is drug-resistance. Usually during therapy, a second cancer-signaling pathway is opened as soon as the primary one shuts down. The investigators of this research concluded that this creates, â€œan ingenious escape route for the cancer cell to survive
Researchers have identified mammalian target of rapamycin (mTOR) as an important mediator of tumor progression. Inhibitors of mTOR signaling may be a promising way to treat a significant number of patients suffering from breast cancer. More specifically, the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays a critical role in multiple cellular functions including metabolism, proliferation, growth and survival . This is a highly conserved pathway in many cancers and is linked to drug-resistance, a common side-effect with many forms of cancer therapy.